1. Acne Drug Could Help Combat Hardening of the Arteries  Technology Networks
  2. Scientists solve the mystery of hardening arteries, and find solution in a common drug  New Atlas
  3. A 22p-a-day acne drug could protect millions from killer heart conditions, scientists say  The Sun
  4. View full coverage on Google News
A generic medication normally used to treat acne could be an effective treatment for hardening of the arteries, according to new animal study.

Acne Drug Could Help Combat Hardening of the Arteries | Technology Networks

A landmark study, led by a team of scientists from King’s College London and the University of Cambridge, has described the mechanism responsible for the hardening of arteries. The research also points to a common antibiotic as a potential new treatment to prevent this condition.A landmark study, led by a team of scientists from King’s College London and the University of Cambridge, has described the mechanism responsible for the hardening of arteries. The research also points to a common antibiotic as a potential new treatment to prevent this condition.

Scientists solve the mystery of hardening arteries, and find solution in a common drug

A CHEAP acne drug could protect millions from killer heart conditions by preventing the deadly hardening of arteries. It may also slash the risk of the second most common form of dementia, which af…

A 22p-a-day acne drug could protect millions from killer heart conditions, scientists say – The Sun

Dichloroacetate, metformin, and rosiglitazone/pioglitazone had the most preclinical data to support use in pulmonary arterial hypertension.Dichloroacetate, metformin, and rosiglitazone/pioglitazone had the most preclinical data to support use in pulmonary arterial hypertension.

New “Old” Therapies in Pulmonary Arterial Hypertension: A Clinical Roundtable - The Cardiology Advisor

Dichloroacetate, metformin, and rosiglitazone/pioglitazone had the most preclinical data to support use in pulmonary arterial hypertension.Dichloroacetate, metformin, and rosiglitazone/pioglitazone had the most preclinical data to support use in pulmonary arterial hypertension.

New “Old” Therapies in Pulmonary Arterial Hypertension: A Clinical Roundtable - Pulmonology Advisor